Az elhízás és a depresszió kapcsolatai

Z. Ríhmer, Purebl György, G. Faludi, Halmy László

Research output: Article

14 Citations (Scopus)

Abstract

It has been long known that the frequency of overweight and obese people is higher among depressed and bipolar patients than in the general population. The marked alteration of body weight (and appetite) is one of the most frequent of the 9 symptoms of major depressive episode, and these symptoms occur during recurrent episodes of depression with a remarkably high consequency. According to studies with representative adult population samples, in case of obesity (BMI over 30) unipolar or bipolar depression is significantly more frequently (20-45%) observable. Since in case of depressed patients appetite and body weight reduction is observable during the acute phase, the more frequent obesity in case of depressed patients is related (primarily) not only to depressive episodes, but rather to lifestyle factors, to diabetes mellitus also more frequently occuring in depressed patients, to comorbid bulimia, and probably to genetic-biological factors (as well as to pharmacotherapy in case of medicated patients). At the same time, according to certain studies, circadian symptoms of depression give rise to such metabolic processes in the body which eventually lead to obesity and insulin resistance. According to studies in unipolar and bipolar patients, 57-68% of patients is overweight or obese, and the rate of metabolic syndrome was found to be between 25- 49% in bipolar patients. The rate of metabolic syndrome is further increased by pharmacotherapy. Low total and HDL cholesterol level increases the risk for depression and suicide and recent studies suggest that omega-3-fatty acids possess antidepressive efficacy. Certain lifestyle factors relevant to healthy metabolism (calorie reduction in food intake, regular exercise) may be protective factors related to depression as well. The depression- and possibly suicide-provoking effect of silbutramine and rimonabant used in the pharmacotherapy of obesity is one of the greatest recent challenges for professionals and patients as well.

Original languageHungarian
Pages (from-to)183-189
Number of pages7
JournalNeuropsychopharmacologia Hungarica
Volume10
Issue number4
Publication statusPublished - okt. 2008

Fingerprint

Obesity
Depression
rimonabant
Appetite
Drug Therapy
Suicide
Life Style
Body Weight
Bulimia
Omega-3 Fatty Acids
Biological Factors
Depressive Disorder
Bipolar Disorder
HDL Cholesterol
Population
Insulin Resistance
Weight Loss
Diabetes Mellitus
Eating
Exercise

Keywords

  • Bipolar disorder
  • Circadian rhythm
  • Depression
  • Life-style
  • Obesity
  • Psychopharmacons

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Neuropsychology and Physiological Psychology
  • Clinical Neurology

Cite this

Az elhízás és a depresszió kapcsolatai. / Ríhmer, Z.; György, Purebl; Faludi, G.; László, Halmy.

In: Neuropsychopharmacologia Hungarica, Vol. 10, No. 4, 10.2008, p. 183-189.

Research output: Article

Ríhmer, Z, György, P, Faludi, G & László, H 2008, 'Az elhízás és a depresszió kapcsolatai', Neuropsychopharmacologia Hungarica, vol. 10, no. 4, pp. 183-189.
Ríhmer, Z. ; György, Purebl ; Faludi, G. ; László, Halmy. / Az elhízás és a depresszió kapcsolatai. In: Neuropsychopharmacologia Hungarica. 2008 ; Vol. 10, No. 4. pp. 183-189.
@article{4d40850cc59545c3ac7e39b3eed7d057,
title = "Az elh{\'i}z{\'a}s {\'e}s a depresszi{\'o} kapcsolatai",
abstract = "It has been long known that the frequency of overweight and obese people is higher among depressed and bipolar patients than in the general population. The marked alteration of body weight (and appetite) is one of the most frequent of the 9 symptoms of major depressive episode, and these symptoms occur during recurrent episodes of depression with a remarkably high consequency. According to studies with representative adult population samples, in case of obesity (BMI over 30) unipolar or bipolar depression is significantly more frequently (20-45{\%}) observable. Since in case of depressed patients appetite and body weight reduction is observable during the acute phase, the more frequent obesity in case of depressed patients is related (primarily) not only to depressive episodes, but rather to lifestyle factors, to diabetes mellitus also more frequently occuring in depressed patients, to comorbid bulimia, and probably to genetic-biological factors (as well as to pharmacotherapy in case of medicated patients). At the same time, according to certain studies, circadian symptoms of depression give rise to such metabolic processes in the body which eventually lead to obesity and insulin resistance. According to studies in unipolar and bipolar patients, 57-68{\%} of patients is overweight or obese, and the rate of metabolic syndrome was found to be between 25- 49{\%} in bipolar patients. The rate of metabolic syndrome is further increased by pharmacotherapy. Low total and HDL cholesterol level increases the risk for depression and suicide and recent studies suggest that omega-3-fatty acids possess antidepressive efficacy. Certain lifestyle factors relevant to healthy metabolism (calorie reduction in food intake, regular exercise) may be protective factors related to depression as well. The depression- and possibly suicide-provoking effect of silbutramine and rimonabant used in the pharmacotherapy of obesity is one of the greatest recent challenges for professionals and patients as well.",
keywords = "Bipolar disorder, Circadian rhythm, Depression, Life-style, Obesity, Psychopharmacons",
author = "Z. R{\'i}hmer and Purebl Gy{\"o}rgy and G. Faludi and Halmy L{\'a}szl{\'o}",
year = "2008",
month = "10",
language = "Hungarian",
volume = "10",
pages = "183--189",
journal = "Neuropsychopharmacologia Hungarica",
issn = "1419-8711",
publisher = "Hungarian Association of Psychopharmacology",
number = "4",

}

TY - JOUR

T1 - Az elhízás és a depresszió kapcsolatai

AU - Ríhmer, Z.

AU - György, Purebl

AU - Faludi, G.

AU - László, Halmy

PY - 2008/10

Y1 - 2008/10

N2 - It has been long known that the frequency of overweight and obese people is higher among depressed and bipolar patients than in the general population. The marked alteration of body weight (and appetite) is one of the most frequent of the 9 symptoms of major depressive episode, and these symptoms occur during recurrent episodes of depression with a remarkably high consequency. According to studies with representative adult population samples, in case of obesity (BMI over 30) unipolar or bipolar depression is significantly more frequently (20-45%) observable. Since in case of depressed patients appetite and body weight reduction is observable during the acute phase, the more frequent obesity in case of depressed patients is related (primarily) not only to depressive episodes, but rather to lifestyle factors, to diabetes mellitus also more frequently occuring in depressed patients, to comorbid bulimia, and probably to genetic-biological factors (as well as to pharmacotherapy in case of medicated patients). At the same time, according to certain studies, circadian symptoms of depression give rise to such metabolic processes in the body which eventually lead to obesity and insulin resistance. According to studies in unipolar and bipolar patients, 57-68% of patients is overweight or obese, and the rate of metabolic syndrome was found to be between 25- 49% in bipolar patients. The rate of metabolic syndrome is further increased by pharmacotherapy. Low total and HDL cholesterol level increases the risk for depression and suicide and recent studies suggest that omega-3-fatty acids possess antidepressive efficacy. Certain lifestyle factors relevant to healthy metabolism (calorie reduction in food intake, regular exercise) may be protective factors related to depression as well. The depression- and possibly suicide-provoking effect of silbutramine and rimonabant used in the pharmacotherapy of obesity is one of the greatest recent challenges for professionals and patients as well.

AB - It has been long known that the frequency of overweight and obese people is higher among depressed and bipolar patients than in the general population. The marked alteration of body weight (and appetite) is one of the most frequent of the 9 symptoms of major depressive episode, and these symptoms occur during recurrent episodes of depression with a remarkably high consequency. According to studies with representative adult population samples, in case of obesity (BMI over 30) unipolar or bipolar depression is significantly more frequently (20-45%) observable. Since in case of depressed patients appetite and body weight reduction is observable during the acute phase, the more frequent obesity in case of depressed patients is related (primarily) not only to depressive episodes, but rather to lifestyle factors, to diabetes mellitus also more frequently occuring in depressed patients, to comorbid bulimia, and probably to genetic-biological factors (as well as to pharmacotherapy in case of medicated patients). At the same time, according to certain studies, circadian symptoms of depression give rise to such metabolic processes in the body which eventually lead to obesity and insulin resistance. According to studies in unipolar and bipolar patients, 57-68% of patients is overweight or obese, and the rate of metabolic syndrome was found to be between 25- 49% in bipolar patients. The rate of metabolic syndrome is further increased by pharmacotherapy. Low total and HDL cholesterol level increases the risk for depression and suicide and recent studies suggest that omega-3-fatty acids possess antidepressive efficacy. Certain lifestyle factors relevant to healthy metabolism (calorie reduction in food intake, regular exercise) may be protective factors related to depression as well. The depression- and possibly suicide-provoking effect of silbutramine and rimonabant used in the pharmacotherapy of obesity is one of the greatest recent challenges for professionals and patients as well.

KW - Bipolar disorder

KW - Circadian rhythm

KW - Depression

KW - Life-style

KW - Obesity

KW - Psychopharmacons

UR - http://www.scopus.com/inward/record.url?scp=63349087646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63349087646&partnerID=8YFLogxK

M3 - Article

C2 - 19213197

AN - SCOPUS:63349087646

VL - 10

SP - 183

EP - 189

JO - Neuropsychopharmacologia Hungarica

JF - Neuropsychopharmacologia Hungarica

SN - 1419-8711

IS - 4

ER -